Welcome to our dedicated page for LENZ THERAPEUTICS news (Ticker: LENZ), a resource for investors and traders seeking the latest updates and insights on LENZ THERAPEUTICS stock.
LENZ Therapeutics, Inc. commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, an FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. Company news centers on U.S. commercialization, product availability, financial results, prescribing and product-revenue updates, and consumer and professional education for the ophthalmic product.
Recurring LENZ developments also include regulatory submissions for VIZZ outside the United States, international licensing and commercialization partnerships, investor-conference participation, and safety or pharmacovigilance communications related to real-world product use. VIZZ is described by the company as a once-daily, preservative-free, single-dose vial product that uses a predominantly pupil-selective miotic mechanism to improve near vision.
LENZ Therapeutics (NASDAQ:LENZ) has received FDA approval for VIZZ™ (aceclidine ophthalmic solution 1.44%), the first and only aceclidine-based eye drop for treating presbyopia in adults. The product represents a breakthrough as the first once-daily solution providing up to 10 hours of improved near vision.
VIZZ works through a unique mechanism of action, contracting the iris sphincter muscle to achieve a sub-2mm pupil without causing myopic shift. The approval was supported by three Phase 3 studies (CLARITY 1, 2, and 3) involving 683 participants, demonstrating consistent efficacy within 30 minutes of application and good tolerability with no serious treatment-related adverse events.
Commercial launch is expected by mid-Q4 2025, with samples available as early as October 2025. The product addresses a significant market of approximately 128 million adults in the United States affected by presbyopia.
LENZ Therapeutics (NASDAQ:LENZ) reported Q2 2025 financial results and significant milestones in their presbyopia treatment program. The company's lead drug candidate LNZ100 has a PDUFA date of August 8, 2025, with FDA review progressing smoothly. LENZ has secured multiple international licensing deals worth over $195 million in potential payments plus double-digit royalties.
The company has completed hiring an 88-member sales force ready for immediate post-approval launch. Financial position remains strong with $209.6 million in cash as of June 30, 2025. Q2 net loss was $14.9 million ($0.53 per share), compared to $10.3 million ($0.40 per share) in Q2 2024.
LENZ Therapeutics (NASDAQ:LENZ) announced that its partner CORXEL Pharmaceuticals has submitted a New Drug Application (NDA) for LNZ100 to China's NMPA for presbyopia treatment. The submission is supported by successful Phase 3 JX07001 clinical trial results, where LNZ100 achieved its primary and secondary endpoints.
The NDA submission triggers the first milestone payment under the April 2022 licensing agreement, under which LENZ is eligible to receive up to $95.0 million in regulatory and sales milestones, plus tiered mid single-digit to low double-digit royalties on Greater China net sales.
LENZ Therapeutics (NASDAQ:LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100, a presbyopia treatment, in Canada. The deal includes over $70 million in upfront and milestone payments, plus double-digit royalties on net sales.
LNZ100, the first and only aceclidine-based eye drop for presbyopia, has a FDA PDUFA date of August 8, 2025. The FDA accepted the NDA in October 2024 and does not plan to hold an Advisory Committee Meeting. The treatment targets a condition affecting 1.8 billion people globally, including 128 million in the United States.
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has announced its participation in three major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference on June 3 in Chicago (presentation at 1:40pm EDT)
- Jefferies Global Healthcare Conference on June 4-5 in New York City (presentation at 9:55am EDT)
- Goldman Sachs Global Healthcare Conference on June 9 in Miami Beach (fireside chat at 4:00pm EDT)
Live webcasts for the Jefferies and Goldman Sachs presentations will be available on LENZ's website, with replays accessible for 12 months. The company will also conduct one-on-one investor meetings at all three conferences.
LENZ Therapeutics (NASDAQ: LENZ) has entered into an exclusive license and commercialization agreement with Lotus Pharmaceutical for LNZ100, a presbyopia treatment eye drop, in Korea and Southeast Asia. The deal includes up to $125 million in upfront and milestone payments, plus double-digit royalties on future sales.
Lotus will have exclusive rights for LNZ100 in Korea, Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia, and Singapore. The agreement targets a market of over 100 million people affected by presbyopia in these regions. The FDA has already accepted LENZ's NDA for LNZ100 with a PDUFA date of August 8, 2025.
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, announced its participation in the BofA Securities 2025 Health Care Conference. The company's management will engage in a fireside chat and one-on-one meetings at the conference, scheduled for May 13-15, 2025 in Las Vegas.
The presentation will take place on Tuesday, May 13, 2025, at 9:20am PDT / 12:20pm EDT at the Encore Hotel. A live audio webcast will be available on LENZ's website, with a replay accessible for 12 months following the event.
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company, has scheduled its first quarter 2025 financial results and corporate highlights webcast for May 7th, 2025, at 4:30 p.m. EDT.
The company specializes in developing an innovative aceclidine-based eye drop designed to enhance near vision for individuals with presbyopia, positioning it as the first and only treatment of its kind.
Interested participants can join via:
- Phone: (800) 715-9871 (Domestic)
- Phone: (646) 307-1963 (International)
- Access Code: 8251197
The webcast will be accessible through the company's website at www.LENZ-tx.com in the Investors & Media section, with a replay available for 30 days following the event.
LENZ Therapeutics (NASDAQ: LENZ) has reported its Q4 and full year 2024 financial results, highlighting significant progress toward the potential approval of LNZ100 for presbyopia treatment. The FDA has set a PDUFA target action date of August 8, 2025, with no Advisory Committee Meeting planned.
Key financial metrics include:
- Cash position of $209.1 million as of December 31, 2024
- Q4 2024 R&D expenses decreased to $5.9 million from $19.5 million in Q4 2023
- Q4 2024 SG&A expenses increased to $9.4 million from $5.5 million in Q4 2023
- Q4 2024 net loss of $12.7 million ($0.46 per share)
The company has completed its mid-cycle review with the FDA and initiated production for commercial launch. Phase 3 study results in China showed positive outcomes, with 74% of patients achieving three-lines or greater improvement at 3 hours. Commercial preparations are advancing with expanded infrastructure and key sales force leadership appointments.